View in EDS HTML Full Text PDF Full Text

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.

Saved in:
Bibliographic Details
Title: Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.
Authors: FitzGerald O; School of Medicine, UCD Conway Institute for Biomolecular Research, University College Dublin, Ireland., Behrens F; Translational Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Barton A; Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK., Bertheussen H; GRAPPA Patient Research Partner, Norway., Boutouyrie-Dumont B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Coates L; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Davies O; UCB Pharma, Slough, UK., de Wit M; GRAPPA Patient Research Partner, Zaltbommel, the Netherlands., Fagni F; Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany., Goodyear CS; School of Infection & Immunity, College of Medical, Veterinar & Life Sciences, University of Glasgow, Glasgow, UK., Gurke R; Pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Hahnefeld L; Pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Huppertz C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ioannidis V; Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Ibberson M; Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Katz A; GRAPPA Patient Research Partner, Israel., Klippstein M; Translational Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Koehm M; Translational Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Korish S; Bristol Myers Squibb, Princeton, NJ, USA., Mackay S; Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Sankt Augustin and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Martin DA; Pfizer Immunology & Inflammation Research Unit, Cambridge, MA, USA., O'Sullivan D; GRAPPA Patient Research Partner, Ireland., Patel K; Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK., Rueping S; Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Sankt Augustin and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Schett G; Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany., Scholich K; Pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence Immune Mediated Diseases, Frankfurt, Germany., Schwenk JM; Affinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden., Siebert S; School of Infection & Immunity, College of Medical, Veterinar & Life Sciences, University of Glasgow, Glasgow, UK., Simon D; Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany., Vivekanantham A; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Pennington SR; School of Medicine, UCD Conway Institute for Biomolecular Research, University College Dublin, Ireland.
Source: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2023 Sep 08; Vol. 15, pp. 1759720X231192315. Date of Electronic Publication: 2023 Sep 08 (Print Publication: 2023).
Publication Type: Journal Article; Review
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101517322 Publication Model: eCollection Cited Medium: Print ISSN: 1759-720X (Print) Linking ISSN: 1759720X NLM ISO Abbreviation: Ther Adv Musculoskelet Dis Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1759-720X
DOI:10.1177/1759720X231192315